12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Deals

Horizon Pharma, Pozen, AstraZeneca deal

Horizon will acquire U.S. rights to Vimovo naproxen/esomeprazole from AstraZeneca for $35 million in cash up front. Horizon will take over U.S. commercialization of Vimovo from AstraZeneca and ongoing U.S. patent litigation for the drug. AstraZeneca, which will retain ex-U.S. rights to Vimovo, is partnered to develop and commercialize the product with Pozen under a 2006 deal. Pozen will remain eligible for 10% royalties on net U.S. sales of Vimovo, with a minimum...

Read the full 351 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >